Anika Therapeutics enters its third-quarter report with something it has not had in years: a credible profitability story. Last quarter the company raised its full-year outlook on revenue, its OEM channel and adjusted EBITDA margin all at once, and it posted its strongest profitability since 2020. The stock has rallied about 25% since then. The question now is whether a quarter that management itself warned would be softer can still show that the improvement is structural rather than a well-timed burst of orders.

Wall Street is braced for a step back. Consensus calls for revenue of $29.4 million, up a modest 5.8% from a year ago but down roughly $3 million from the $32.6 million reported in the second quarter. Earnings are expected at just $0.02 per share, a big swing from the $0.17 loss a year ago yet far below last quarter's $0.30. That sequential drop is not a surprise. Management flagged that $1 million to $2 million of second-quarter OEM revenue was order timing pulled forward, and its OEM guidance of flat to 5% growth for the year implies a meaningful second-half slowdown in that channel.

The full-year math suggests the Street is leaning cautious. Anika guided to 2026 revenue of roughly $118.5 million to $124.1 million, and consensus of $118.6 million sits at the very bottom of that range. With first-half revenue already at $62 million, a $29.4 million third quarter would leave a fourth quarter around $27 million to hit consensus. That leaves room for upside if the commercial business keeps its pace, but it also signals skepticism that the first-half strength will carry through. The margin guide tells a similar story: a 13% to 17% adjusted EBITDA margin for the year, after roughly 18% in the first half, implies lower second-half profitability. A result that holds margins closer to the first-half level would be the clearest sign that the operating leverage is real.

The operational evidence that matters most sits outside the OEM channel. Gross margin climbed from 56% to 65% over four quarters, and management now describes the mid-60s as the new normal, helped by completed manufacturing projects that doubled throughput at a Monovisc and Cingal bottleneck and upgraded the OrthoVisc line. Holding that level on lower volume would validate the claim. International revenue hit a record $12.6 million last quarter, and Integrity sales were up 39% year to date on heavy overseas stocking orders. Stocking orders can be lumpy, so continued sell-through rather than a post-stocking lull would strengthen the commercial growth case, which management narrowed to 12% to 18% for the year. Persistent U.S. pricing pressure in osteoarthritis pain products remains the offset to watch.

Two other threads deserve attention. Free cash flow lagged last quarter as June shipments inflated receivables, and management pushed positive cash generation into the second half, making collections this quarter a practical test. Hyalofast is the wild card: the company was preparing its response to an FDA deficiency letter, with the co-primary endpoints identified as the key review issue. Because U.S. Hyalofast sales were stripped from the 2027 outlook, any progress is pure upside, while delays would not dent guidance but would weigh on the longer-term story.

Sentiment has cooled noticeably, slipping to barely bullish from a much warmer reading ahead of the last report, even as the stock trades well above its 200-day average and about 6% below its post-earnings high. That mix suggests the rally has priced in a good deal of the turnaround while enthusiasm about the next leg has faded. The verdict will hinge on whether Anika can absorb the OEM normalization while keeping gross margins in the mid-60s and commercial growth intact. Do that, and the raised guidance looks conservative. Fall short, and last quarter's inflection may start to look like a timing story.